Table 1 Baseline characteristics of the cohort of newly diagnosed COPD patients identified between 2014 and 2018 in the PHARMO Data Network
Characteristic* | Overall | No exacerbation during follow-up | ≥ 1 exacerbation during follow-up |
|---|---|---|---|
N = 8020 | N = 5786 | N = 2234 | |
n (%) | n (%) | n (%) | |
Age at CED (years), mean ± SD | 65.4 ± 10.7 | 65.5 ± 10.6 | 67.6 ± 10.6 |
Female sex | 3797 (47) | 2681 (46) | 1116 (50) |
SES** | |||
Low | 3255 (41) | 2333 (40) | 922 (41) |
Middle | 3124 (39) | 2256 (39) | 868 (39) |
High | 1635 (20) | 1191 (21) | 444 (20) |
Unknown | 6 (< 0.5) | 6 (< 0.5) | 0 (0) |
Obesity** | 919 (11) | 684 (12) | 235 (11) |
Diabetes mellitus type-2 | 1076 (13) | 715 (12) | 361 (16) |
Disorders of lipoprotein metabolism and other lipidaemias | 1503 (19) | 1113 (19) | 390 (17) |
Ischaemic heart disease | 1393 (17) | 959 (17) | 434 (19) |
Hypertensive disease | 3001 (37) | 2073 (36) | 928 (42) |
Heart failure | 547 (7) | 328 (6) | 219 (10) |
Pulmonary oedema | 40 (< 0.5) | 22 (< 0.5) | 18 (1) |
Pulmonary hypertension | 32 (< 0.5) | 17 (< 0.5) | 15 (1) |
Venous thromboembolism | 310 (4) | 210 (4) | 100 (4) |
Arrhythmia | 864 (11) | 563 (10) | 301 (13) |
Cerebrovascular disease | 763 (10) | 532 (9) | 231 (10) |
Asthma | 940 (12) | 676 (12) | 264 (12) |
Chronic kidney disease or renal failure | 387 (5) | 250 (4) | 137 (6) |
Severe mental illness and/or anxiety disorder | 1564 (20) | 1106 (19) | 458 (21) |
Number of GP visits** | |||
Mean ± SD | 5.7 ± 7.0 | 5.4 ± 6.5 | 6.5 ± 7.9 |
Median (IQR) | 4 (0–8) | 4 (0–8) | 4 (0–10) |
Cardiac medication use** | 3778 (47) | 2423 (42) | 1355 (61) |
Metabolic medication use** | 2722 (34) | 1784 (31) | 938 (42) |